Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.6452W HIGH $29.52
Volume
10.16 K
Value Traded
13.04 M
Short % Float
16.16%
+1.49%Week
+12.02%1 Month
+37.87%3 Month
+26.71%6 Month
-7.11%5 Year
+163%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.10 B
EPS (TTM)
1.85
P/E Ratio
13.98
Ent. Value
807.78 M
Total Shares
42.53 M
Float Shares
30.91 M
Insiders
27.34%
Institutions
68.06%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AMPH Catalyst Timeline
Dated clinical, regulatory and corporate events for Amphastar Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amphastar Pharmaceuticals, Inc.
224Total events
1Upcoming
66Tier-1 (high impact)
2014 to 2026Coverage
Upcoming catalysts 1
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 50
▲Milestone PaymentBAQSIMIApprovedCorporate
Achieved first annual net sales milestone for BAQSIMI, triggering $100M payment to Lilly
●NDA SubmissionRegulatory Filing
One ANDA and one biosimilar insulin candidate filed with FDA
▲Product LaunchepinephrineApprovedPost-Market
Planned commercial launch of Ipratropium Bromide HFA Inhalation Aerosol
maintenance treatment of bronchospasm associated with COPDsource ↗
▲FDA ApprovalepinephrineApprovedFDA Decision
FDA approval of Ipratropium Bromide HFA Inhalation Aerosol ANDA
maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysemasource ↗
▲Exclusivity GrantedepinephrineApprovedIP / Competition
180-day generic drug exclusivity granted for Ipratropium Bromide HFA
maintenance treatment of bronchospasm associated with COPDsource ↗
▲Partnership / LicenseAMP-110Corporate
Exclusive license agreement with Nanjing Hanxin for AMP-110
inflammatory and autoimmune conditionssource ↗
▲Partnership / LicenseCorporate
Exclusive license agreement for fully synthetic corticotropin compound with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
▲FDA Approvaliron sucrose injectionApprovedFDA Decision
FDA approval of iron sucrose injection
iron deficiencysource ↗
▲Product Launchiron sucrose injectionApprovedPost-Market
Launch of iron sucrose injection
iron deficiencysource ↗
▲Partnership / LicenseCorporate
Exclusive license agreement with Nanjing Anji Biotechnology for three novel peptides
oncology and ophthalmologysource ↗
▲Partnership / LicenseCorporate
Exclusive licensing agreement with Nanjing Anji Biotechnology for three proprietary peptides
oncology and ophthalmologysource ↗
▲FDA Filing AcceptedAMP-004FiledRegulatory Filing
FDA acceptance of AMP-004 insulin biosimilar application
insulinsource ↗
●Manufacturing MilestoneCMC / Inspection
Multi-year plan to quadruple manufacturing capacity at Rancho Cucamonga headquarters
▲FDA Approvaliron sucrose injectionApprovedFDA Decision
FDA approval of iron sucrose injection
iron deficiencysource ↗
▲FDA Approvalteriparatide injectionApprovedFDA Decision
FDA approval of teriparatide injection
osteoporosissource ↗
▲Partnership / LicenseCorporate
In-licensed three proprietary peptides and a fully synthetic corticotropin compound
oncology, ophthalmology, inflammatory/autoimmunesource ↗
●BLA SubmissionAMP-004FiledRegulatory Filing
BLA submission for Insulin Aspart (AMP-004)
diabetessource ↗
●Product LaunchBAQSIMIApprovedPost-Market
BAQSIMI revenue recognition transition expected to be phased in by country during 2024
diabetessource ↗
◆Timing GuidanceBAQSIMIApprovedPresentation
BAQSIMI revenue recognition change expected phased in by country during 2024
severe hypoglycemiasource ↗
▼Equity OfferingCorporate
Proposed private offering of $300M convertible senior notes due 2029
▲AcquisitionBAQSIMIApprovedCorporate
Amphastar completes acquisition of BAQSIMI from Lilly
severe hypoglycemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How AMPH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-16 | Rextovy (naloxone hydrochloride) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$17M
Pipeline Value
$1.7B
Commercial Value
Undervalued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 76%
Micro Cap(rank 500 of 658)
Percentile Rank
Amphastar Pharmaceuticals, Inc. faces pipeline headwinds (27/100), with $86M risk-adjusted pipeline value, led by I004 in Pharmacokinetics (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $730M x 2.3 = $1.7B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| BAQSIMI | $178M | $167M | +6.6% |
| Primatene MIST | $108M | $107M | +0.5% |
| Epinephrine | $71M | $75M | -5.2% |
| Lidocaine | $56M | $59M | -4.4% |
| Glucagon | $49M | $94M | -48.1% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I004 Small moleculeCompletedNCT05539872 | Pharmacokinetics | Phase 2 | COMPLETED | 131 | Jan 30, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every AMPH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PETERS WILLIAM JDirector, Officer (CFO, EVP & TREASURER) | Sell | -4,139 168,707 held | $25.00 | 09/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AMPH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in AMPH for Q2 2026. | ||||
AMPH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AMPH ranks across every disease it competes in
Competitive Position is a premium feature
See how AMPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAMPH News
AMPHAmphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
Amphastar Pharmaceuticals will present at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. CFO Bill Peters and EVP Tony Marrs will represent the company, discussing its financial performance and business strategies. The presentation will be accessible via webcast for 30 days following the event.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar Pharmaceuticals reported a 5% increase in net revenues to $183.9 million for Q2 2026, alongside a GAAP net income of $30.3 million. The company highlighted successful product launches and a significant milestone payment related to BAQSIMI. However, some product sales faced challenges due to pricing pressures and competition. Overall, the results reflect a strong performance amidst competitive dynamics.
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
Amphastar Pharmaceuticals announced it will release its second quarter earnings for 2026 on August 6, 2026, after market close. A conference call to discuss the financial results will take place at 2:00 p.m. Pacific Time. The call will be accessible via phone and webcast, with a replay available on the company's website.
Read more →AMPHAmphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Amphastar Pharmaceuticals announced that CFO Bill Peters and EVP Jacob Liawatidewi will present at the 2026 Jefferies Healthcare Conference on June 3, 2026. The presentation will be available via webcast for 30 days post-event. This engagement underscores Amphastar's commitment to investor relations and transparency.
Read more →AMPH▼ -20.9%on this news
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Amphastar Pharmaceuticals reported financial results for Q1 2026, achieving net revenues of $171.2 million and a GAAP net income of $6.4 million. The company highlighted the successful launch of Ipratropium Bromide HFA and advancements in its product pipeline. However, it faced challenges with decreased sales in certain products due to pricing and competition.
Read more →AMPH▼ -5.3%on this news· ran to -29% by day 3
insulin aspart biosimilar FDA Approval
Amphastar Pharmaceuticals announced the FDA approval of an insulin aspart biosimilar. The company focuses on developing and commercializing various pharmaceutical products and emphasizes the uncertainty of future projections and performance.
Read more →AMPH▼ -5.3%on this news· ran to -29% by day 3
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Amphastar Pharmaceuticals reported its financial results for the year ended December 31, 2025, highlighting a strategic focus on commercial strength and scientific innovation. The company experienced sustained growth from its product BAQSIMI and received FDA approvals for new complex generics. However, both net revenues and GAAP net income saw decreases compared to the prior year, with particular declines noted in glucagon sales. The company is also advancing multiple proprietary product candidates targeting significant market opportunities.
Read more →AMPHAmphastar Announces FDA Approval for Ipratropium Bromide HFA
Amphastar Pharmaceuticals has received FDA approval for its Ipratropium Bromide HFA Inhalation Aerosol, confirming it as bioequivalent to Boehringer Ingelheim's Atrovent®HFA. The product is eligible for 180 days of generic exclusivity, starting upon launch. Amphastar plans to introduce this inhalation aerosol in early Q2 2026, aiming to enhance its respiratory product offerings.
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. will announce its fourth quarter earnings for 2025 on February 26, 2026, after market close. A conference call is scheduled for 2:00 p.m. Pacific Time to discuss the financial results. The call will be accessible via phone and webcast, with a replay available shortly after.
Read more →AMPH▲ +6%on this news
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions
Amphastar Pharmaceuticals has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical for the development of AMP-110, a fully synthetic ACTH analog targeting inflammatory and autoimmune conditions. This new addition is seen as crucial for expanding Amphastar's peptide portfolio. The agreement includes an upfront payment, milestone payments, and royalty arrangements which could yield significant revenue. AMP-110 is currently undergoing early-phase clinical trials, suggesting a promising safety profile compared to traditional products.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
Amphastar Pharmaceuticals announced its financial results for the quarter ending September 30, 2025, highlighting a 14% revenue growth for its product BAQSIMI. The company received FDA approval for iron sucrose injection, expanding its offerings and enhancing patient access. Despite this, GAAP net income saw a significant decline, and overall product revenues experienced mixed results, with notable drops in some key product sales. Additionally, the company entered into a licensing agreement for three novel peptides aimed at high-growth markets, positioning itself for future growth.
Read more →AMPH▲ +10.9%on this news
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications
Amphastar Pharmaceuticals has entered into an exclusive licensing agreement with Nanjing Anji Biotechnology Co., Ltd. to develop and commercialize three novel peptide products in the U.S. and Canada. These include a peptide aimed at cancer suppression, a docetaxel conjugate designed to improve selectivity and safety, and a topical eye drop for wet age-related macular degeneration. The agreement outlines substantial financial commitments and milestone payments, further bolstering Amphastar's focus on innovative pharmaceutical developments to address pressing medical needs.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
Amphastar Pharmaceuticals has reported strong financial results for the second quarter ended June 30, 2025, highlighting a 21% sales increase in BAQSIMI. The company announced a strategic plan to quadruple its manufacturing capacity, addressing the need to strengthen U.S. operations amid global supply chain risks. Despite this positive momentum, net revenues and GAAP net income showed declines compared to the prior year, owing to reduced sales in certain product categories. The company is also emphasizing a commitment to sustainable growth and advancing its research and development pipeline.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Amphastar Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025, highlighting net revenues of $170.5 million, reflecting a slight decrease from the prior year's $171.8 million. Notably, product revenues from BAQSIMI surged by 177%, while Primatene MIST also saw a 20% increase. However, GAAP net income experienced a significant decline to $25.3 million, down 41% from the previous year. The company expressed confidence in its pipeline development, particularly with the recent FDA acceptance of the AMP-004 biosimilar insulin application.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
Amphastar Pharmaceuticals reported its financial results for the fourth quarter and full year ending December 31, 2024. The company achieved net revenues of $186.5 million for the fourth quarter, a 5% increase, and surpassed its long-term goal for Primatene MIST sales with over $100 million achieved in 2024. However, they saw declines in revenues for certain products like Glucagon and Epinephrine, and an increase in cost of revenues was reported. Future growth is anticipated from a robust pipeline, including biosimilars and generic drugs targeting high market sizes.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 24 Reports Net Revenues of $191.2 Million for the Three Months Ended
Amphastar Pharmaceuticals reported financial results for the third quarter of 2024, highlighting net revenues of $191.2 million, a 6% increase from the previous year. Growth was notably driven by sales of BAQSIMI and Primatene MIST, with the company aiming for sustainable expansion through proprietary products and biosimilars. However, there were challenges, including a decrease in GAAP net income and impact from Hurricane Helene causing shipment delays. The company has also authorized a $50 million increase to its share buyback program to enhance shareholder value.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 24 Reports Net Revenues of $182.4 Million for the Three Months Ended
Amphastar Pharmaceuticals has announced its financial results for the second quarter of 2024, showcasing notable growth with net revenues of $182.4 million, up 25% year-over-year. The success of BAQSIMI is highlighted as a key factor in sales growth, alongside a rise in net income to $37.9 million. However, the company faced challenges with certain products experiencing significant revenue declines. Additionally, costs of revenue increased, affecting overall profit margins.
Read more →AMPHAmphastar Announces Additional $50 Million Increase to its Share Buyback Program
Amphastar Pharmaceuticals has announced a $50 million increase to its share buyback program approved by the Board of Directors. This initiative aims to counteract the dilution caused by the company's equity compensation strategies. The share repurchases may occur through various means, depending on market conditions and regulatory compliance. Amphastar also reported ongoing development efforts for several drugs, targeting significant market sizes across multiple product categories.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended
Amphastar Pharmaceuticals reported strong financial results for the first quarter of 2024, showcasing a 23% increase in net revenues to $171.8 million compared to the same period in 2023. Notable contributors to this growth include a 22% rise in BAQSIMI revenues, reflecting successful product integration. Additionally, the company's net income doubled to $43.2 million, indicating improved profitability. However, the rise in the cost of revenues and declines in certain product revenues raise concerns about ongoing operational challenges.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20 23 Reports Net Revenues of $178.1 Million for the Three Months Ended
Amphastar Pharmaceuticals announced strong financial results for the quarter and year ending December 31, 2023, reporting net revenues of $178.1 million for Q4 2023, an increase of 32% year-over-year. The company's success was driven by notable sales growth in glucagon and the acquisition of BAQSIMI, enhancing its diabetes management offerings. The announcement highlighted a successful submission of a Biologics License Application for Insulin Aspart (AMP-004), indicating ongoing pipeline development. Overall, Amphastar enters 2024 with positive momentum and a robust financial performance.
Read more →About Amphastar Pharmaceuticals, Inc.
Headquarters11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730
Founded1996
BIOPHARMAWATCH ELITE PLUS
Trade the next AMPH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime